FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1801-1806 December 9, 1999 Number 24 Next

	Full Text PDF Editorial by Volkmar, F. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Secretin is a peptide hormone that stimulates pancreatic secretion. After recent publicity about a child with autism whose condition markedly improved after a single dose of secretin, thousands of children with autistic disorders may have received secretin injections.

Methods We conducted a double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in 60 children (age, 3 to 14 years) with autism or pervasive developmental disorder. The children were randomly assigned to treatment with an intravenous infusion of synthetic human secretin (0.4 µg per kilogram of body weight) or saline placebo. We used standardized behavioral measures of the primary and secondary features of autism, including the Autism Behavior Checklist, to assess the degree of impairment at base line and over the course of a four-week period after treatment.

Results Of the 60 children, 4 could not be evaluated — 2 received secretin outside the study, and 2 did not return for follow-up. Thus, 56 children (28 in each group) completed the study. As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures. Among the children in the secretin group, the mean total score on the Autism Behavior Checklist at base line was 59.0 (range of possible values, 0 to 158, with a larger value corresponding to greater impairment), and among those in the placebo group it was 63.2. The mean decreases in scores over the four-week period were 8.9 in the secretin group and 17.8 in the placebo group (mean difference, –8.9; 95 percent confidence interval, –19.4 to 1.6; P=0.11). None of the children had treatment-limiting adverse effects. After they were told the results, 69 percent of the parents of the children in this study said they remained interested in secretin as a treatment for their children.

Conclusions A single dose of synthetic human secretin is not an effective treatment for autism or pervasive developmental disorder.

Source Information

From the Olson Huff Center for Child Development, Thoms Rehabilitation Hospital, Asheville, N.C. (A.D.S., J.D., M.A.G., V.S.); the Human Development Research and Training Institute, Western Carolina Center, Morganton, N.C. (K.A.S., J.W.B.); and the Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill (J.W.B.).

Address reprint requests to Dr. Sandler at the Olson Huff Center for Child Development, Thoms Rehabilitation Hospital, 68 Sweeten Creek Rd., Asheville, NC 28803, or at adsandler{at}pol.net.

Full Text of this Article

This article has been cited by other articles:

• Duggan, C. P., Westra, S. J., Rosenberg, A. E. (2007). Case 23-2007 -- A 9-Year-Old Boy with Bone Pain, Rash, and Gingival Hypertrophy. NEJM 357: 392-400 [Full Text]  
• Woodard, C., Groden, J., Goodwin, M., Bodfish, J. (2007). A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism 11: 29-41 [Abstract]  
• Ratliff-Schaub, K., Carey, T., Reeves, G. D., Rogers, M. A.M. (2005). Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism 9: 256-265 [Abstract]  
• Ng, S. S.M., Chow, B. K.C., Wong, V. C.N. (2005). The Human Secretin Gene in Children With Autistic Spectrum Disorder: Screening for Polymorphisms and Mutations. J Child Neurol 20: 701-704 [Abstract]  
• Lilienfeld, S. O. (2005). Scientifically Unsupported and Supported Interventions for Childhood Psychopathology: A Summary. Pediatrics 115: 761-764 [Abstract] [Full Text]  
• Davis, R. J., Page, K. J., Dos Santos Cruz, G. J., Harmer, D. W., Munday, P. W., Williams, S. J., Picot, J., Evans, T. J., Sheldrick, R. L., Coleman, R. A., Clark, K. L. (2004). Expression and Functions of the Duodenal Peptide Secretin and its Receptor in Human Lung. Am. J. Respir. Cell Mol. Bio. 31: 302-308 [Abstract] [Full Text]  
• Levy, S E, Souders, M C, Wray, J, Jawad, A F, Gallagher, P R, Coplan, J, Belchic, J K, Gerdes, M, Mitchell, R, Mulberg, A E (2003). Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Arch. Dis. Child. 88: 731-736 [Abstract] [Full Text]  
• White, J. F. (2003). Intestinal Pathophysiology in Autism. Exp. Biol. Med. 228: 639-649 [Abstract] [Full Text]  
• Banks, W. A., Goulet, M., Rusche, J. R., Niehoff, M. L., Boismenu, R. (2002). Differential Transport of a Secretin Analog across the Blood-Brain and Blood-Cerebrospinal Fluid Barriers of the Mouse. J. Pharmacol. Exp. Ther. 302: 1062-1069 [Abstract] [Full Text]  
• Lightdale, J. R., Hayer, C., Duer, A., Lind-White, C., Jenkins, S., Siegel, B., Elliott, G. R., Heyman, M. B. (2001). Effects of Intravenous Secretin on Language and Behavior of Children With Autism and Gastrointestinal Symptoms: A Single-Blinded, Open-Label Pilot Study. Pediatrics 108: e90-90 [Abstract] [Full Text]  
• Yung, W.-H., Leung, P.-S., Ng, S. S. M., Zhang, J., Chan, S. C. Y., Chow, B. K. C. (2001). Secretin Facilitates GABA Transmission in the Cerebellum. J. Neurosci. 21: 7063-7068 [Abstract] [Full Text]  
• Corbett, B., Khan, K., Czapansky-Beilman, D., Brady, N., Dropik, P., Goldman, D. Z., Delaney, K., Sharp, H., Mueller, I., Shapiro, E., Ziegler, R. (2001). A Double-Blind, Placebo-Controlled Crossover Study Investigating the Effect of Porcine Secretin in Children with Autism. CLIN PEDIATR 40: 327-331 [Abstract]  
• Asano, E., Kuivaniemi, H., Mahbubul Huq, A.H.M., Tromp, G., Behen, M., Rothermel, R., Herron, J., Chugani, D. C. (2001). A Study of Novel Polymorphisms in the Upstream Region of Vasoactive Intestinal Peptide Receptor Type 2 Gene in Autism. J Child Neurol 16: 357-363 [Abstract]  
• Roberts, W., Weaver, L., Brian, J., Bryson, S., Emelianova, S., Griffiths, A.-M., MacKinnon, B., Yim, C., Wolpin, J., Koren, G. (2001). Repeated Doses of Porcine Secretin in the Treatment of Autism: A Randomized, Placebo-Controlled Trial. Pediatrics 107: 71e-71 [Abstract] [Full Text]  
• Halsey, N. A., Hyman, S. L., the Conference Writing Panel, (2001). Measles-Mumps-Rubella Vaccine and Autistic Spectrum Disorder: Report From the New Challenges in Childhood Immunizations Conference Convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics 107: 84e-84 [Abstract] [Full Text]  
• Committee on Children With Disabilities, (2001). Technical Report: The Pediatrician's Role in the Diagnosis and Management of Autistic Spectrum Disorder in Children. Pediatrics 107: 85e-85 [Abstract] [Full Text]  
• Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gotzsche, P. C., Lang, T., for the CONSORT Group, (2001). The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. ANN INTERN MED 134: 663-694 [Abstract] [Full Text]  
• Rapin, I. (2001). An 8-Year-Old Boy With Autism. JAMA 285: 1749-1757 [Full Text]  
• Feudtner, C. (2001). Child Advocacy and Robust Community-Centered Research. Arch Pediatr Adolesc Med 155: 438-439 [Full Text]  
• Gringras, P. (2000). Practical Paediatric Psychopharmacological Prescribing in Autism: The Potential and the Pitfalls. Autism 4: 229-247 [Abstract]  
• Siegel, B. (2000). Synthetic human secretin did not improve symptoms or communication skills in children with autistic disorders. Evid. Based Ment. Health 3: 52-52 [Full Text]  
• Horvath, K., Rimland, B., Herlihy, W. C., Said, S. I., Bodanszky, M., Sandler, A., Volkmar, F. (2000). Secretin Treatment for Autism. NEJM 342: 1216-1218 [Full Text]  
• Kemp, C. (2000). . AAP News 16: 2-3 [Full Text]  
• (2000). Secretin Fails to Improve Autism. JWatch Psychiatry 2000: 2-2 [Full Text]  
• Volkmar, F. R. (1999). Lessons from Secretin. NEJM 341: 1842-1845 [Full Text]